InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Walker TJ, Risendal B, Kegler MC, Friedman DB, Weiner BJ, Williams RS, Tu SP, Fernandez ME. Assessing Levels and Correlates of Implementation of Evidence-Based Approaches for Colorectal Cancer Screening: A Cross-Sectional Study With Federally Qualified Health Centers. Health Educ Behav. 2018 12; 45(6):1008-1015. PMID: 29991294; PMCID: PMC6226355.
      Citations: 7     Fields:    Translation:Humans
    2. Fernandez ME, Walker TJ, Weiner BJ, Calo WA, Liang S, Risendal B, Friedman DB, Tu SP, Williams RS, Jacobs S, Herrmann AK, Kegler MC. Developing measures to assess constructs from the Inner Setting domain of the Consolidated Framework for Implementation Research. Implement Sci. 2018 03 27; 13(1):52. PMID: 29587804; PMCID: PMC5870186.
      Citations: 53     Fields:    Translation:Humans
    3. Krist AH, Woolf SH, Hochheimer C, Sabo RT, Kashiri P, Jones RM, Lafata JE, Etz RS, Tu SP. Harnessing Information Technology to Inform Patients Facing Routine Decisions: Cancer Screening as a Test Case. Ann Fam Med. 2017 05; 15(3):217-224. PMID: 28483886; PMCID: PMC5422082.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    4. Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med. 2016 Mar; 109(3):98-105. PMID: 26933155; PMCID: PMC4794967.
      Citations: 8     Fields:    Translation:Humans
    5. Tu SP, Young VM, Coombs LJ, Williams RS, Kegler MC, Kimura AT, Risendal BC, Friedman DB, Glenn BA, Pfeiffer DJ, Fernandez ME. Practice adaptive reserve and colorectal cancer screening best practices at community health center clinics in 7 states. Cancer. 2015 Apr 15; 121(8):1241-8. PMID: 25524651; PMCID: PMC4393345.
      Citations: 7     Fields:    Translation:Humans
    6. Tu SM. Cancer: a "stem-cell" disease? Cancer Cell Int. 2013 May 06; 13(1):40. PMID: 23647946; PMCID: PMC3651409.
      Citations: 10     
    7. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012 Oct 23; 107(9):1547-53. PMID: 23033003; PMCID: PMC3493771.
      Citations: 15     Fields:    Translation:Humans
    8. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012 Aug 07; 107(4):646-51. PMID: 22805323; PMCID: PMC3419961.
      Citations: 4     Fields:    Translation:Humans
    9. Tu SM, Chen AH. Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol. 2012 Jun; 19(3):6268. PMID: 22704311.
      Citations:    Fields:    Translation:Humans
    10. Tu SM, Lin SH. Prostate cancer stem cells. Clin Genitourin Cancer. 2012 Jun; 10(2):69-76. PMID: 22421313; PMCID: PMC4141775.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    11. He XX, Tu SM, Lee MH, Yeung SJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011 Dec; 22(12):2640-2645. PMID: 21415239; PMCID: PMC3221513.
      Citations: 68     Fields:    Translation:Humans
    12. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51. PMID: 20551894; PMCID: PMC4993042.
      Citations: 4     Fields:    Translation:HumansCells
    13. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):811-5. PMID: 20052472; PMCID: PMC4436674.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    14. Tu SM. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. Cancer Treat Res. 2010; 154:v-239. PMID: 20645140.
      Citations: 19     Fields:    Translation:HumansCells
    15. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80. PMID: 19402048.
      Citations: 20     Fields:    Translation:Humans
    16. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24. PMID: 19414670; PMCID: PMC4371137.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    17. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    18. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. PMID: 18362942; PMCID: PMC2361701.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    19. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J. 2008 Jan-Feb; 14(1):35-9. PMID: 18303481.
      Citations: 8     Fields:    Translation:HumansCells
    20. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J. 2007 Apr; 29(4):813-5. PMID: 17400880.
      Citations: 3     Fields:    Translation:Humans
    21. Tu SP, Taylor V, Yasui Y, Chun A, Yip MP, Acorda E, Li L, Bastani R. Promoting culturally appropriate colorectal cancer screening through a health educator: a randomized controlled trial. Cancer. 2006 Sep 01; 107(5):959-66. PMID: 16865681.
      Citations: 73     Fields:    Translation:HumansPHPublic Health
    22. Tu SP, Chen H, Chen A, Lim J, May S, Drescher C. Clinical trials: understanding and perceptions of female Chinese-American cancer patients. Cancer. 2005 Dec 15; 104(12 Suppl):2999-3005. PMID: 16247796; PMCID: PMC1810650.
      Citations: 34     Fields:    Translation:Humans
    23. Seng P, Acorda E, Carey Jackson J, Marchand A, Thai H, Tu SP, Taylor V. AANCART best practices: cancer awareness activities for Seattle's Combodian community. Cancer. 2005 Dec 15; 104(12 Suppl):2916-9. PMID: 16276540; PMCID: PMC1811046.
      Citations:    Fields:    Translation:Humans
    24. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10. PMID: 16258090.
      Citations: 16     Fields:    Translation:Humans
    25. Tu SP, Yasui Y, Kuniyuki AA, Schwartz SM, Jackson JC, Hislop TG, Taylor V. Mammography screening among Chinese-American women. Cancer. 2003 Mar 01; 97(5):1293-302. PMID: 12599238; PMCID: PMC1618781.
      Citations: 27     Fields:    Translation:Humans
    26. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60. PMID: 12085204; PMCID: PMC2746595.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    27. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001 Aug; 166(2):521-5. PMID: 11458058.
      Citations: 42     Fields:    Translation:Humans
    28. Park DS, Vassilopoulou Sellin R, Tu S. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. Urology. 2001 Jul; 58(1):105. PMID: 11445494.
      Citations: 1     Fields:    Translation:Humans
    29. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41. PMID: 11210994.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    30. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 01; 89(3):615-8. PMID: 10931461.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    31. Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med. 1998 Jun; 1(6):953-9. PMID: 9852630.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    32. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201. PMID: 9607577.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    33. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5. PMID: 9474150.
      Citations: 10     Fields:    Translation:Humans
    34. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 01; 80(11):2128-32. PMID: 9392335.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    35. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500. PMID: 9815652.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    36. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6. PMID: 9815636.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    37. Westin P, Lo P, Marin M, Fernandez A, Sarkiss M, Tu S, Brisbay S, Voneschenbach A, McDonnell T. bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int J Oncol. 1997 Jan; 10(1):113-8. PMID: 21533353.
      Citations:    Fields:    
    38. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996 Nov-Dec; 2(6):191-7. PMID: 21224168.
      Citations: 5     Fields:    
    39. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995 Nov; 154(5):1719-22. PMID: 7563331.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    40. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995 Sep; 13(9):2272-7. PMID: 7666085.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    41. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett. 1995 Jul 13; 93(2):147-55. PMID: 7621422.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    42. McDonnell TJ, Marin MC, Hsu B, Brisbay SM, McConnell K, Tu SM, Campbell ML, Rodriguez-Villanueva J. The bcl-2 oncogene: apoptosis and neoplasia. Radiat Res. 1993 Dec; 136(3):307-12. PMID: 8278571.
      Citations: 6     Fields:    Translation:HumansAnimals
    43. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett. 1992 Aug 31; 65(3):215-20. PMID: 1355405.
      Citations: 12     Fields:    Translation:Humans
    44. Deckmyn H, Tu SM, Majerus PW. Guanine nucleotides stimulate soluble phosphoinositide-specific phospholipase C in the absence of membranes. J Biol Chem. 1986 Dec 15; 261(35):16553-8. PMID: 3023354.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    45. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer. PLoS One. 10.
    46. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Annals of Oncology. 26:2125-2132.
    47. Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation. Clinical Genitourinary Cancer.
    48. Expression of bcl-2 and its correlation with the development of androgen independent. Cancer Bulletin. 45:448-452.
    49. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi. Annals of Oncology. 26:2507-2508.
    50. Radium-223. ONCOLOGY (United States). 29.
    51. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer.
    52. Intratumoral heterogeneity. Cancer.
    53. Phase I-II study of Gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 12:365-370.
    54. Postacute Care in Cancer Rehabilitation. Physical Medicine and Rehabilitation Clinics of North America. 28:19-34.
    55. Corrigendum. Cancer Letters. 99:247.
    56. Stem cells in carcinogenesis of the prostate. 73-79.
    57. Editorial comment. Canadian Journal of Urology. 19:6268.
    58. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    59. Clinically atypical seminomas with yolk sac tumor features. Canadian Journal of Urology. 20:6860-6867.
    60. A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urologic Oncology: Seminars and Original Investigations. 1:156-160.
    61. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 4.
    TU's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (266)
    Co-Authors (24)
    Similar People (59)
    Same Department Expand Description